Background
:
Type 2 diabetes mellitus (DM) is an incurable chronic disease
needs long life treatment. So,
the study of long
-
term safety and tolerability of oral hypoglycemic agents especially newer one is very
important. The objective of this study was to compare safety and efficacy of vildagliptin
with glimepiride
in
type 2 dia
betic patients.
Patients & Methods
:
40 patients with type 2 DM were randomized to receive
vildagliptin
50 mg or glimepiride 2 mg once daily as add
-
on therapy for 16 weeks. A vildagliptin
group (23
patients) was received 50 mg vildagliptin
once daily as add
-
on therapy, and glimepiride group (17 patients) was
received 2 mg once daily as add
-
on therapy. The end point was the number of patients achieving HbA
1C
(Glycated haemoglobin)
0.05
).
. Weight of patients in vildagliptin
group were reduced while in glimepiride group there was increase in weight (
-
5.2 kg. vs. + 4.3kg, p
˂ 0.05).
There was statistically significant difference in patient weights in both groups.
Conclusion
:
Vildagliptin
is
effective as hypoglycemic agent, as glimepiride in controlling blood glucose level guided by reduction in fasting
blood sugar and HbA1C. In addition to reduction in patient weight and is well tolerated